AIMS: Improved prostate cancer (PCa)-specific biomarkers are urgently required to distinguish between indolent and aggressive disease, in order to avoid overtreatment. In this study, we investigated the prostatic tissue expression of secreted frizzled-related protein (SFRP)-2. METHODS AND RESULTS: Following immunohistochemical analysis on PCa tissue microarrays with samples from 216 patients, strong/moderate SFRP-2 expression was observed in epithelial cells of benign prostatic hyperplasia, and negative/weak SFRP-2 expression was observed in the majority of tumour epithelia. However, among Gleason grade 5 carcinomas, 40% showed strong/moderate SFRP-2 expression and 60% showed negative SFRP-2 expression in epithelial cells. Further microscopic evaluation of Gleason grade 5 tumours revealed different morphological patterns, corresponding with differential SFRP-2 expression. The first subgroup (referred to as Type A) appeared to have a morphologically solid growth pattern, whereas the second subgroup (referred to as Type B) appeared to have a more diffuse pattern. Furthermore, 100% (4/4) of Type A patients experienced biochemical recurrence, as compared with 0% (0/6) of Type B patients. CONCLUSIONS: These results imply: (i) that there is a loss of SFRP-2 expression from benign to malignant prostate glands; and (ii) differential SFRP-2 expression among two possible subgroups of Gleason grade 5 tumours.
AIMS: Improved prostate cancer (PCa)-specific biomarkers are urgently required to distinguish between indolent and aggressive disease, in order to avoid overtreatment. In this study, we investigated the prostatic tissue expression of secreted frizzled-related protein (SFRP)-2. METHODS AND RESULTS: Following immunohistochemical analysis on PCa tissue microarrays with samples from 216 patients, strong/moderate SFRP-2 expression was observed in epithelial cells of benign prostatic hyperplasia, and negative/weak SFRP-2 expression was observed in the majority of tumour epithelia. However, among Gleason grade 5 carcinomas, 40% showed strong/moderate SFRP-2 expression and 60% showed negative SFRP-2 expression in epithelial cells. Further microscopic evaluation of Gleason grade 5 tumours revealed different morphological patterns, corresponding with differential SFRP-2 expression. The first subgroup (referred to as Type A) appeared to have a morphologically solid growth pattern, whereas the second subgroup (referred to as Type B) appeared to have a more diffuse pattern. Furthermore, 100% (4/4) of Type A patients experienced biochemical recurrence, as compared with 0% (0/6) of Type B patients. CONCLUSIONS: These results imply: (i) that there is a loss of SFRP-2 expression from benign to malignant prostate glands; and (ii) differential SFRP-2 expression among two possible subgroups of Gleason grade 5 tumours.
Authors: Carmen J Marsit; Margaret R Karagas; Angeline Andrew; Mei Liu; Hadi Danaee; Alan R Schned; Heather H Nelson; Karl T Kelsey Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Jürgen Veeck; Erik Noetzel; Nuran Bektas; Edgar Jost; Arndt Hartmann; Ruth Knüchel; Edgar Dahl Journal: Mol Cancer Date: 2008-11-06 Impact factor: 27.401
Authors: Y Y Cheng; J Yu; Y P Wong; E P S Man; K F To; V X Jin; J Li; Q Tao; J J Y Sung; F K L Chan; W K Leung Journal: Br J Cancer Date: 2007-09-11 Impact factor: 7.640
Authors: Antoinette S Perry; Gillian O'Hurley; Omer A Raheem; Kevin Brennan; Simon Wong; Anthony O'Grady; Anne-Marie Kennedy; Laure Marignol; Therese M Murphy; Linda Sullivan; Ciara Barrett; Barbara Loftus; John Thornhill; Stephen M Hewitt; Mark Lawler; Elaine Kay; Thomas Lynch; Donal Hollywood Journal: Int J Cancer Date: 2012-09-28 Impact factor: 7.396
Authors: Huensuk Kim; Seungyeul Yoo; Ruoji Zhou; An Xu; Jeffrey M Bernitz; Ye Yuan; Andreia M Gomes; Michael G Daniel; Jie Su; Elizabeth G Demicco; Jun Zhu; Kateri A Moore; Dung-Fang Lee; Ihor R Lemischka; Christoph Schaniel Journal: Proc Natl Acad Sci U S A Date: 2018-11-01 Impact factor: 11.205